Prognostic Role of High Sensitivity Troponin T (hsTnT) After Recanalization of Chronic Total Occlusions (CTO)

Background: The prognostic role of periprocedural hsTnT after percutaneous coronary intervention (PCI) of CTOs is unknown. We evaluated the incidence and impact of hsTnT elevations on clinical and angiographic outcomes after CTO-PCI. Methods: In a retrospective database analysis we identified 309 successfully treated CTO-PCI patients that had a re-angiography 6 months after the initial procedure. Both catheterizations were used for quantitative coronary angiography (QCA). HsTnT was measured before and 18-24 h after CTO-PCI. According to periinterventional hsTnT release patients were divided into 4 quartiles (QI: 0-99 ng/l; QII: 100-199 ng/l; QIII: 200-299 ng/l; QIV: >= 300 ng/l) and correlated with QCA and clinical data. Results: Mean age of the patient population was 67 +/- 10.6 years. The antegrade approach was used in 91% of the procedures. After treatment, in-CTO-segment minimal lumen diameter (MLD) was 2.97 +/- 0.42 mm. On 6 months follow up In-CTO-segment MLD decreased to 2.74 +/- 0.71 mm which corresponded to an In-CTO-segment late lumen loss (LLL) of 0.23 +/- 0.45 mm. Target lesion revascularization rate (TLR) occurred in 21 of 309 patients (6.8%). Higher periinterventional hsTnT release (QIII-IV) was associated with more frequent TLR compared to lower hsTnT release (QI-II) (28.6% vs. 4%; p < 0.0001). In a multivariable model hsTnT release emerged as an independent predictor of TLR (OR 7.3; 95% CI 2.12-26.9). Conclusions: Our findings suggest that hsTnT release is associated with increased TLR. Therefore, periinterventional hsTnT measurement might be useful in the risk stratification of CTO procedures. (C) 2020 Elsevier Inc. All rights reserved.